Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
The Gene Fusion Assay data looks good.www.biocartis.com/en/publications/onl... The Combination of EGFR and Gene fusion really fills out the Idylla Lung Cancer menu. I have to watch it, I'm having another one of those BCART optimistic episodes. If they can move both gene fusion and EGFR to a fully approved IVD, they could really fill a niche for smaller lower throughput labs, hospitals. I'm basing this optimism on the following: The price point for the Idylla console will look good good relative to the Thermo (Oncomine) or Illumina Minseq platform costs; All of the major actionable fusions are covered. The speed and ease of Idylla use; No genetic counseling is required to interpret results; The following video from a competitor's site identifies factors that should be considered for choosing a platform for NTRK fusions. They identify several factors that appear to be positives for Idylla.www.ntrktesting.com/optimizing-ngs-fo... Strange that BCART really downplays this information. FL
keep the faith and be patient... i think this will work in the future for biocartis ! ik zit er al lang in en wordt met de dag optimistischer , nu de koers nog ...
en zo is het maar net. Hou VOL !
I read a very interesting report concerning Precision Medicine and MDx testing. I'd highly encourage anyone investing in BCART to read the following: "Pharma Precision Readiness Report 2020, NCLS an axis of Change" Diaceutics November 2020docsend.com/view/cztpstzsehqtfit3 It was free but I doubt that the link will work since they want you to sign in with Diaceutics. There were several interesting figures and key take aways: On average 3 to 6 years are required between biomarker test introduction and widescale use/reimbursement. Laboratory developed testing LDT constitutes between 40 to 70% of the biomarker NSCLC testing currently being done. These tests currently undergo little in the way of FDA approvals in the U.S. Correspondingly, as many as 60% of the insurance reimbursement requests may be denied since the LDT is largely unapproved; Figure 7 is particularly interesting Currently (in 2020) there are 7 targeted NSCLC drugs that act on a specific molecular pathway. They collectively represented $5.3Billion in sales. There are 2050 molecular pathology labs offering IHC MDx testing. Collectively they have NSCLC revenues of $125 million. Hence, the reports major finding is that there is a major imbalance in the reimbursement rate for the MDx labs vs the the Pharma companies, considering the value they bring to the process. Diaceutics has a decidedly lab based focus but it becomes very apparent that the market is extremely fragmented and wide open for disintermediation. Speed, automation, available on demand, and cost reduction are huge factors in favor of Idylla. However, the market is presently commoditized with hundreds of MDx providers keeping a lid on the biomarker testing/reimbursement costs. On the bright side, if Idylla can secure registrations and CPT reimbursement codes their costs, speed, ease of use are factors that favor the Idylla MDx testing platform, so they could be in a good position to disintermediate the industry. On the downside, before they secure the IVD registration approvals they are in a very crowded market. I still believe that there is a place for both PCR and NGS winners, but this really needs to be the inflection year. FL
The interesting thing about the Thailand marketing is that it appears that most assays are registered and approved for diagnostic use. I'm basing this on the observation that ct EGFR is listed as RUO and the majority of the others are not listed as RUO. Not a big country or market but they are likely to carry the EGFR mutation at higher levels like other Asian populations. Also, the price point for Idylla should be attractive in Thailand relative to NGS. FL
Great to see how shorters are being squeezed out in US markets.
Yep, but it remains unseen how the Robin Hooder's will exit these positions. It is likely that some new investors that are just chasing momentum get crushed. But I do enjoy watching some of the Hedge funds have to squirm looking for a bailout. FL
I love it, the reddit forum is going mad over this and even big boys are jumping on the mad-train. Late last night, Melvin had to be financied for 3billion just to keep it's head above water.
Flatlander schreef op 28 januari 2021 14:05 :
Yep, but it remains unseen how the Robin Hooder's will exit these positions. It is likely that some new investors that are just chasing momentum get crushed. But I do enjoy watching some of the Hedge funds have to squirm looking for a bailout.
FL
De late instappers gaan vele miljarden verlies lijden.
One of the few times I agree with DZR. This is being portrayed as the little guy millennial on reddit rising up against the system. I think we'll eventually find that there are more orchestrated/sophisticated origins to these short squeezes. FL
It's exactly what they accuse hedge funds of doing, screwing over the little guy. With of course the instigators and lucky early adopters who got out & loaded. Rest massive loss
On the market someone always pays the price, that's the game we're into, and the risk we are willing to take when buying stocks. Stocks like tesla are also very much overpriced, I don't see anyone complaining there.. Let's not forget the billions and billions of money that companies like citadel already made with their short positions, also in this company by the way. Also reason why BCART had to pay off short position not long ago, what was that all about. Look @ what's going on today with brooker Robinhood not allowing buying of these stocks anymore, only selling.. pure manipulation of the market.. I see some kind of panic in Wallstreet, and I do not particularly think that's a bad thing.
Cepheid Blow out 4th Qtr The Cepheid COVID test has noted advantages over Idylla: It runs in half the time (45 min); It can be configured to analyze up to 80 cartridges at a time; Combination cartridges that include flu are available; and More than 10X the number of Cepheid consoles deployed. None the less, it does show the promise of the business model. The point about placing consoles where they can drive future cartridge consumption is especially relevant to BCART. FLwww.genomeweb.com/business-news/danah... "Meanwhile, Cepheid, part of the Diagnostics segment, saw more than 100 percent core growth and passed $2 billion in annual revenue, one year after hitting the $1 billion mark, Blair said, and Radiometer and Leica Biosystems, also housed in Diagnostics, both had high single-digit revenue growth in the quarter. During the quarter, Cepheid shipped approximately 9 million test cartridges, and Blair said the firm expects to ship 9 million during each quarter this year. Approximately 60 percent of the respiratory tests shipped were for SARS-CoV-2 only, while 40 percent were the 4-in-1 test for SARS-CoV-2, influenza A/B, and respiratory syncytial virus, he added. In Asia, there was a preference for the SARS-CoV-2-only test because the flu isn't as prevalent there, but in Europe there has been increasing adoption of the 4-in-1 test, although it's been staggered country by country, Blair said. Cepheid also placed "a record number" of new GeneXpert systems, increasing its installed base 35 percent in 2020 to more than 30,000 instruments globally. Blair said the company has been thoughtful in placing those instruments, so they will "find great utilization" in the long term once COVID-19 testing demand has decreased."
Seems Robinhood is also working together with Citadel, that bailed out Melvin Capital. How ironic is that!www.tijd.be/ondernemen/banken/robinho...
Hi Flatlander, That means Cepheid can deploy 160 cartridges per 90 minutes, while biocartis could do only 6. Howmuch does it cost for a cartridge op Cepheid? If they are more or less in the same price range, then i start to understand why biocartis doesn't find any traction... ? Can you help me see why hospitals should choose biocartis above cepheid? kind regards JotieP
JotieP I see $19.80 per cartridge.www.finddx.org/pricing/genexpert/ The Genexpert Cepheid system has a decade head start on BCART. They were the first mover in the POC infectious disease POC market. I think the similarity of the Cepheid system is one of the reasons BCART indicated their focus was oncology. The move into infectious disease was initiated to salvage what would otherwise be a lost year. Oncology POC MDx still has no dominant provider, so I think BCARTs decision was correct at the time. A number of MDx companies changed focus to make up for the reduced volumes. EXAS did the same and has salvaged their year, HTGM didn't make the move and has struggled. FL
Flat I read somewhere that our beloved ( in case of Biocartis) Thermo Fischer sells 40 % of the Corona tests in the world. That’s pretty impressive baering in mind the number of testing worldwide . So i do find it a bit strange that they were dashing Biocartis cause it does operate in a niche market ( oncologie) and are realy no competition for big players like Cepheid and Exas on their domain . I like to think they would of want to have a slice of the worldwide oncologie testing also and that’s a big market too . So this can only have a few reasons either they see no future in the technologie , or it’s too expensive , or ....... . Lastly i want to ask if you know Genprex inc they developped imunotherapie for the oncologie last stage market . Their going into phase 3 , all that i read from them is pretty impressive so i took the gamble and bought a slice ( 4,32 )
Gijpie Fisher is very focused on the POC market. Last years attempted acquisition of Quidel and this years acquisition of Mesa provide proof of their intent to bulk up as a POC. provider. Fisher offers MDx products that compete head to head with Idylla. The new Lung cancer Gene Fusion Assay's is direct competition to Fisher's Ocomine fusion test. That said the Fisher exchange provides the largest MDx platform and is used by hundreds of companies in the field. I think they would distribute Idylla products without bias in an agnostic manner if the customer knew exactly what they wanted. If they did not do this I'm sure they would have been sued by now. I just don't think that Fisher would go out of their way to recommend Idylla over their own products. BCART really needed a dedicated sales force that could market, educate and trouble shoot on behalf of clients. I think it was the right decision, but it will take years to play out. EXAS is putting most of their eggs in the liquid biopsy basket. It seems like they are committed to expanding their laboratory testing program rather than moving into the POC market. If the technology is able to detect circulating tumors at low concentration and then be able to identify the organ where the cancer originated from, it will be a practice changing home run technology. I think BCART is more of a singles and doubles type of technology. BCART needs for the registration to allow diagnostic use so it can be used as a CDx. The technology looks like it would be a good fit in emerging markets with less access to NGS and also in some smaller hospitals and medical practices. However, the fact is that most Dr's don't have access to MDx data when initially prescribing treatment. the field is evolving albeit, slowly. As I have said in the past, the growth trajectory of Idylla could play out like Cepheids Gene Expert over a decade or more. We are very early in the roll-out. I would look for signals as we come out of the pandemic as to where the greatest traction exists. meticulousblog.org/top-10-companies-i... www.prnewswire.com/news-releases/ther... I really do not know much about Genprex, so I'll need to do some reading. FL
Septicyte Rapid Presentation Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants FLwww.prnewswire.com/news-releases/immu...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee